Analysts Offer Insights on Healthcare Companies: and Catabasis Pharmaceuticals (CATB)
There’s a lot to be optimistic about in the Healthcare sector as 1 analysts just weighed in on and Catabasis Pharmaceuticals (CATB) with bullish sentiments.
Catabasis Pharmaceuticals (CATB)
In a report issued on May 13, Hartaj Singh from Oppenheimer reiterated a Buy rating on Catabasis Pharmaceuticals, with a price target of $60.00. The company’s shares closed last Monday at $6.91.
According to TipRanks.com, Singh is a 5-star analyst with an average return of 10.3% and a 45.4% success rate. Singh covers the Healthcare sector, focusing on stocks such as Alexion Pharmaceuticals, Vertex Pharmaceuticals, and Strongbridge Biopharma.
Currently, the analyst consensus on Catabasis Pharmaceuticals is a Moderate Buy with an average price target of $37.50, implying a 473.4% upside from current levels. In a report issued on June 11, Wedbush also reiterated a Buy rating on the stock with a $15.00 price target.
See today’s analyst top recommended stocks >>
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CATB: